Syeda Mahrukh Hussnain Naqvi
Overview
Explore the profile of Syeda Mahrukh Hussnain Naqvi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DePalo D, Dugan M, Naqvi S, Ollila D, Hieken T, Block M, et al.
Cancer
. 2024 Nov;
131(1):e35636.
PMID: 39522025
Background: Isolated limb infusion and perfusion (ILI/ILP) has been a mainstay treatment for unresectable melanoma in-transit metastases (ITM), but increased use of immune checkpoint inhibitors (ICI) and intralesional therapy (talimogene...
2.
Vince M, Naqvi S, Pellini B, Verbosky M, Melzer D
Lung Cancer
. 2024 Nov;
198:107999.
PMID: 39500124
Background: Small cell lung cancer (SCLC) is an aggressive disease associated with high relapse rates and limited treatment options. Current standard of care treatment for extensive-stage disease includes combination chemotherapy...
3.
Aflatooni S, Dugan M, Boby A, Ghali H, DePalo D, Naqvi S, et al.
Ann Surg Oncol
. 2024 Oct;
32(1):568-569.
PMID: 39446227
No abstract available.
4.
Aflatooni S, Dugan M, Boby A, Ghali H, DePalo D, Naqvi S, et al.
Ann Surg Oncol
. 2024 Sep;
31(13):9272-9280.
PMID: 39256312
Background: Isolated limb infusion (ILI) treats unresectable extremity malignancies with high-dose regional chemotherapy limited to the limb. This study assessed long-term outcomes after ILI for limb-threatening sarcomas. Methods: A retrospective...
5.
Robertson S, Yasukawa M, Marchion D, Xiong Y, Naqvi S, Gheit T, et al.
PLoS One
. 2023 Dec;
18(12):e0294448.
PMID: 38039311
Introduction: Currently 11 infectious agents are classified as carcinogenic but the role of infectious agents on outcomes of epithelial ovarian cancer is largely unknown. Objective: To explore the association between...
6.
Zhao X, Boothe P, Naqvi S, Henderson-Jackson E, Mela N, Centeno B, et al.
J Am Soc Cytopathol
. 2022 Aug;
11(6):368-374.
PMID: 35995701
Introduction: Rapid on-site evaluation (ROSE) has been used during the endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) procedure as standard practice. Because of the COVID-19 (coronavirus disease 2019) pandemic, our institute...
7.
Carr M, Sun J, Depalo D, Rothermel L, Song Y, Straker R, et al.
Ann Surg Oncol
. 2021 Oct;
29(2):791-801.
PMID: 34648098
Background: Talimogene laherparepvec (T-VEC) is an oncolytic virus approved for the treatment of unresectable, recurrent melanoma. The role of T-VEC after progression on systemic immunotherapy (IO) remains undefined. The goal...
8.
Broman K, Hughes T, Dossett L, Sun J, Kirichenko D, Carr M, et al.
Cancer
. 2021 Apr;
127(13):2251-2261.
PMID: 33826754
Background: For patients with sentinel lymph node (SLN)-positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease-specific survival (DSS) with active surveillance using nodal ultrasound versus completion lymph...
9.
Elmariah H, Naqvi S, Kim J, Nishihori T, Mishra A, Perez L, et al.
Bone Marrow Transplant
. 2021 Mar;
56(7):1683-1690.
PMID: 33658647
Higher infused total nucleated cell dose (TNC) in allogeneic bone marrow transplant (BMT) with post-transplant cyclophosphamide (PTCy) is associated with improved overall survival. As many centers prefer peripheral blood stem...
10.
Carr M, Sun J, Kroon H, Miura J, Beasley G, Farrow N, et al.
Ann Surg Oncol
. 2020 Sep;
27(13):5107-5118.
PMID: 32918177
Background: Isolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose chemotherapy to extremities affected by locally advanced or in-transit melanoma. This study compared the outcomes of melanoma...